Regeneus Ltd. (AU:CMB)
ASX:CMB
Top Page
Regeneus Ltd.
(Sydney:CMB)
Select Model
Select Model
Rating:43Neutral
Price Target:
AU$0.40
▼(-15.74% Downside)
Action:ReiteratedDate:04/01/26
The score is held down primarily by weak financial quality—large losses and accelerating cash burn despite a modest revenue rebound—along with bearish technical signals (below major moving averages and negative MACD). Valuation is difficult to assess due to negative earnings and no dividend information, providing only limited support.
Positive Factors
Revenue rebound & gross margin
FY2025 showed a meaningful revenue rebound alongside a high gross margin (~69%), indicating the company can monetize its offerings with favorable unit economics. Sustained gross margins provide a durable foundation for future scalability and imply product-level profitability potential as sales grow.
Negative Factors
Severe cash burn
FY2025 operating and free cash flows were deeply negative (~-A$5.24m and -A$5.25m), indicating acute cash burn. Persistent negative cash generation shortens runway and forces dilutive capital raises or program cuts, constraining the firm’s ability to fund critical clinical and commercialization activities over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue rebound & gross margin
FY2025 showed a meaningful revenue rebound alongside a high gross margin (~69%), indicating the company can monetize its offerings with favorable unit economics. Sustained gross margins provide a durable foundation for future scalability and imply product-level profitability potential as sales grow.
Read all positive factors
Regeneus Ltd. (CMB) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$11.21M
Dividend YieldN/A
Average Volume (3M)3.93K
Price to Earnings (P/E)―
Beta (1Y)-3.17
Revenue GrowthN/A
EPS GrowthN/A
CountryAU
EmployeesN/A
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.07
Shares Outstanding27,331,919
10 Day Avg. Volume7,693
30 Day Avg. Volume3,926
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)2.09
Price to Sales (P/S)5.73
P/FCF Ratio-0.73
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Regeneus Ltd. Business Overview & Revenue Model
Company Description
Cambium Bio Limited, a clinical-stage regenerative medicine company, focuses on developing biologics for ophthalmology and tissue repair applications. The company provides lead product candidate is Elate Ocular for the treatment of dry eye disease...
How the Company Makes Money
null...
Regeneus Ltd. Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
48
Neutral
Cash Flow
18
Very Negative
| Breakdown | Jun 2024 | Jun 2023 | Jun 2023 | Jun 2021 | Jun 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 670.06K | 719.00 | 0.00 | 0.00 | 7.07M |
| Gross Profit | 464.32K | 719.00 | -6.42K | -24.96K | 0.00 |
| EBITDA | -3.80M | -1.98M | -3.09M | -4.74M | 2.37M |
| Net Income | -3.84M | -2.26M | -3.38M | -4.31M | 2.76M |
Balance Sheet | |||||
| Total Assets | 3.30M | 5.65M | 2.48M | 2.55M | 8.51M |
| Cash, Cash Equivalents and Short-Term Investments | 166.41K | 2.86M | 302.79K | 164.40K | 3.79M |
| Total Debt | 482.71K | 468.32K | 1.95M | 1.01M | 13.84K |
| Total Liabilities | 1.46M | 2.87M | 4.43M | 1.48M | 4.36M |
| Stockholders Equity | 1.84M | 2.78M | -1.81M | 1.07M | 4.15M |
Cash Flow | |||||
| Free Cash Flow | -5.25M | -155.86K | -659.66K | -3.60M | 2.41M |
| Operating Cash Flow | -5.24M | -155.86K | -660.46K | -3.59M | 2.42M |
| Investing Cash Flow | -333.48K | -416.13K | -48.13K | -8.47K | -7.78K |
| Financing Cash Flow | 2.88M | 3.13M | 916.27K | -97.83K | 400.00K |
Regeneus Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | AU$6.91M | -3.15 | -17.07% | ― | ― | 71.10% | |
44 Neutral | AU$10.20M | -0.48 | 1068.18% | ― | ― | 31.87% | |
44 Neutral | AU$9.76M | -1.25 | -140.35% | ― | ― | ― | |
43 Neutral | AU$11.21M | -1.00 | -218.76% | ― | ― | ― | |
40 Underperform | AU$2.17M | -4.31 | -32.19% | ― | ― | 46.43% |
* Healthcare Sector Average
AU:CMB
Regeneus Ltd.
0.41
0.13
46.43%
ZLDAF
Zelira Therapeutics
0.34
0.04
12.37%
AU:IXC
Invex Therapeutics Ltd.
0.09
0.02
31.43%
AU:1AD
AdAlta Ltd.
―
―
―
AU:BGT
Bio-Gene Technology Ltd.
0.03
>-0.01
-3.03%
AU:HXL
Hexima Ltd
0.01
0.00
0.00%
Regeneus Ltd. Corporate Events
Cambium Bio Director Increases Stake Through Share Placement
Mar 24, 2026
Cambium Bio Limited has disclosed a change in director Yu-Hung Sebastian Tseng’s interests following a recent share placement. Tseng, who holds shares directly and through Zheng Yang Biomedical Technology Limited, increased his indirect hold...
Cambium Bio Issues New Shares Under Cleansing Notice, Affirms Regulatory Compliance
Mar 16, 2026
Cambium Bio Limited has issued 4,363,637 new ordinary shares without a prospectus under provisions of the Corporations Act, and lodged the associated Appendix 2A with the ASX. The company confirmed it is up to date with its financial reporting and...
Cambium Bio Seeks ASX Quotation for 4.36 Million New Shares
Mar 16, 2026
Cambium Bio Limited has applied for quotation on the ASX of 4,363,637 new ordinary fully paid shares, to be traded under its existing ticker CMB. The new securities, issued on March 17, 2026, form part of a previously announced transaction and wil...
Cambium Bio Wins Strong Shareholder Backing for Capital-Raising Resolutions
Mar 16, 2026
Cambium Bio shareholders have strongly backed all resolutions put to an extraordinary general meeting, with each motion passed by poll. The approvals included the issue of placement shares to Zheng Yang Biomedical Technology and authority to issue...
Cambium Bio Narrows Half-Year Loss and Turns NTAs Positive as Revenue Grows
Feb 19, 2026
Cambium Bio Limited reported a 9% rise in revenue from ordinary activities to $327,000 for the half-year ended 31 December 2025, alongside other income of $584,000, reflecting modest top-line growth as it advances its regenerative medicine program...
Cambium Bio Plans Significant Share Placement to Raise Equity
Feb 11, 2026
Cambium Bio Limited has notified the ASX of its intention to issue up to 21,276,596 new fully paid ordinary shares under a proposed placement or similar capital-raising structure. The new securities, expected to be issued in mid-June 2026, signal ...
Cambium Bio Calls Vote on Share Placement to Boost Major Holder’s Control
Feb 11, 2026
Cambium Bio Limited has called an online general meeting for 16 March 2026, asking shareholders to approve the issue of 4,363,637 placement shares to Zheng Yang Biomedical Technology Co., Ltd. The proposed placement would lift the combined relevan...
Cambium Bio Secures Funding and Advances Toward Phase 3 Trials for Elate Ocular
Jan 22, 2026
Cambium Bio has strengthened its funding position ahead of pivotal Phase 3 trials of its dry eye candidate Elate Ocular®, receiving a A$0.6 million RD Tax Incentive refund under an approved Advance Overseas Finding that provides a 43.5% cash ...
Cambium Bio Plans Share Placement to Raise Fresh Capital
Jan 19, 2026
Cambium Bio Limited has announced a proposed placement of up to 4,363,637 new fully paid ordinary shares on the ASX, with an expected issue date of 17 March 2026. The capital raising signals an effort to strengthen the company’s balance shee...
Cambium Bio Raises A$2.4m at Premium from Major Shareholder to Fund Phase 3 Dry Eye Trials
Jan 19, 2026
Cambium Bio has secured a A$2.4 million strategic equity investment from major shareholder and long-term partner ZYBT via a placement of 4,363,637 new shares at A$0.55, a 20% premium to the last closing price, which will increase ZYBT’s stak...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.